Results 181 to 190 of about 1,455,615 (310)

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Shifting sands in Saudi Arabian healthcare system towards value-based care: navigating the changing landscape. [PDF]

Front Public Health
Al-Jedai A, Almudaiheem H, Aburas WIS, Almutairi E, Eshmawi MT, Al Sulaiman K, Tawfik E, Al-Luhidan M, Alowairdhi M, Awad N, Ojeil R, Alshennawi MA.   +11 more
europepmc   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Provincial stratification and equity-weighted cost-effectiveness of malaria vaccines in Zambia under climate variability. [PDF]

BMJ Public Health
Phiri AE.
europepmc   +1 more source

Intergenerational Linkages and Government Budget Policies [PDF]

Quarterly Review, 1987
openaire   +3 more sources

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Financing of Trauma and Burn Prevention and Care in Malawi: A Scoping Review. [PDF]

Health Sci Rep
Aminu K, Adegbile OE, Omobowale O, Jayasinghe YA, Olorunlana A, Nnannah PC, Okeke E, Eze UA, Salami AA, Nwebo RA, Kanmodi KK.   +10 more
europepmc   +1 more source

Training without jobs is a waste of aid: why Japan's partnership with the World Bank must tackle the 'fiscal space' for health workforce. [PDF]

BMJ Glob Health
Kubota K.
europepmc   +1 more source

Center on Budget Policy and Priorities: A Guide to Budget for NGOs

Financijska teorija i praksa, 2003
The Center on Budget and Policy Priorities (CBPP) iz Washingtona, odnosno The International Budget Project (IBP) kao dio tog Centra, objavio je 1999. godine Vodič kroz proračune u praksi za nevladine udruge (A Guide to Budget Work for NGOs) kako bi javnosti i institucijama pomogao u boljem razumijevanju proračunske problematike. Od 1999.
openaire   +2 more sources

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer, Eliza J. McEwin, Zhicheng Wang, Joel Lexchin, Barbara Mintzes   +4 more
wiley   +1 more source